SAFETY AND IMMUNOGENICITY OF INACTIVATED HEPATITIS-A VACCINE IN PATIENTS WITH CHRONIC LIVER-DISEASE

The safety and immunogenicity of inactivated hepatitis A vaccine was e valuated in patients with chronic liver disease. Sixty hepatitis A vir us antibody (anti-HAV) seronegative patients with chronic liver diseas e (56 chronic hepatitis B and four chronic hepatitis C) and from 17 to 47 years of age received a dose of 1440 ELISA units of the inactivate d hepatitis A vaccine at month 0, and a booster at month 6. Anti-HAV s eroconversion (greater than or equal to 33 mlU/mL) was 57.6% (34/59) o n day 15, and reached 93.2% (55/59) 1 month after primary vaccination. At month 6, the seropositivity of anti-HAV decreased before the boost er to 69.0% (40/58). All vaccinees had measurable titers of anti-HAV 1 month after booster vaccination, and were still seropositive at month 12. After initial vaccination, the geometric mean titers of anti-HAV among vaccine responders were 158, 264, 74, 1309, and 409 mlU/ml at da y 15 and months 1, 6, 7, and 12. Overall, 59.7% (71/119) of the vaccin e doses administered were followed by mostly minor reactions. The majo rity of symptoms reported were local, all of which resolved within 3 d ays after vaccination. No significant changes in serum liver enzyme le vels were detected after vaccination. Thus, an inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the imm une response was inferior to that observed in healthy subjects reporte d in a previous study. (C) 1997 Wiley-Liss, Inc.